Purpose: This scoping review contributes to understanding the utilization of end-of-life anticancer drugs in gastrointestinal cancer patients, a topic posing significant public health challenges due to its prevalence, impact on morbidity and mortality, and associated healthcare costs. Insight into unique treatment patterns at the end of life is vital for enhancing the appropriateness of cancer care for these patients. Methods: Extensive searches were conducted in Medline and Embase to locate articles on the use of anticancer drugs in the end-of-life phase of gastrointestinal cancer patients. Results: We identified 30 publications and described treatment frequencies alongside methodological characteristics. On average, 7.0% and 13.2% of patients received anticancer drugs in the last two and four weeks of life, respectively, with 3.3% commencing new anticancer regimens in the final four weeks. Conclusion: This review offers a comprehensive overview of primary studies reporting end-of-life treatments in gastrointestinal cancer patients. However, methodological inconsistencies present significant challenges, highlighting a notable proportion of patients potentially experiencing overtreatment. Therefore, there is a pressing need for more standardized research methods to ensure robust evaluations and enhance the quality of care for these patients.